GSK has reported that Blenrep achieved an important secondary outcome in the DREAMM-7 study.

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly’s real-time, streaming news feed keeps individual…

Read More: https://thefly.com/permalinks/entry.php/id4022089/GSK-GSK-announces-Blenrep-met-key-secondary-endpoint-in-DREAMM-trial1731582977